Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 2
2006 1
2007 3
2008 3
2009 2
2010 7
2011 5
2012 4
2013 11
2014 11
2015 13
2016 7
2017 7
2018 8
2019 4
2020 1
2021 6
2022 8
2023 11
2024 9
2025 14
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Cipriani A, et al. Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21. Lancet. 2018. PMID: 29477251 Free PMC article.
In terms of efficacy, all antidepressants were more effective than placebo, with ORs ranging between 2.13 (95% credible interval [CrI] 1.89-2.41) for amitriptyline and 1.37 (1.16-1.63) for reboxetine. For acceptability, only agomelatine (OR 0.84, 95% CrI 0.72-0.97) and flu …
In terms of efficacy, all antidepressants were more effective than placebo, with ORs ranging between 2.13 (95% credible interval [CrI] 1.89- …
Efficacy and Safety of Agomelatine in Depressed Patients with Diabetes: A Systematic Review and Meta-Analysis.
Gędek A, Modrzejewski S, Materna M, Szular Z, Wichniak A, Mierzejewski P, Dominiak M. Gędek A, et al. Int J Mol Sci. 2024 Nov 25;25(23):12631. doi: 10.3390/ijms252312631. Int J Mol Sci. 2024. PMID: 39684343 Free PMC article.
Following PRISMA guidelines, a total of 11 studies were identified, both preclinical and clinical trials. Agomelatine has shown great potential as a treatment option for patients with diabetes and comorbid depression and anxiety. ...Research should also focus on identifyin …
Following PRISMA guidelines, a total of 11 studies were identified, both preclinical and clinical trials. Agomelatine has shown great …
Efficacy and safety of agomelatine in the treatment of patients with depressive disorder: A meta-analysis.
Guo YH, Zhou L, Cui ZA, Wang J, Zhang L, Xu T, Xie YD, Chen H. Guo YH, et al. Medicine (Baltimore). 2023 Nov 10;102(45):e35871. doi: 10.1097/MD.0000000000035871. Medicine (Baltimore). 2023. PMID: 37960759 Free PMC article.
OBJECTIVE: To systematically assess the efficacy and safety of agomelatine in the treatment of patients with depressive disorder. METHODS: Randomized controlled trials (RCTs) related to agomelatine in the treatment of patients with depressive disorder published in P …
OBJECTIVE: To systematically assess the efficacy and safety of agomelatine in the treatment of patients with depressive disorder. MET …
Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.
Stein DJ, Khoo JP, Picarel-Blanchot F, Olivier V, Van Ameringen M. Stein DJ, et al. Adv Ther. 2021 Mar;38(3):1567-1583. doi: 10.1007/s12325-020-01583-9. Epub 2021 Feb 4. Adv Ther. 2021. PMID: 33537871 Free PMC article.
Significant effects were also found for symptom response on the HAM-A (67.1% of patients on agomelatine vs. 32.5% on placebo) and symptom remission (38.8% of patients on agomelatine vs. 17.3% on placebo). Compared to placebo, there was a significant difference in fa …
Significant effects were also found for symptom response on the HAM-A (67.1% of patients on agomelatine vs. 32.5% on placebo) and sym …
Effects of Agomelatine on Sleep Across Populations: A Systematic Review and Meta-Analysis.
Stefanou A, Anastasiou I, Fallon P, Glarou E, Christodoulou N, Lappas AS, Bozikas VP, Samara MT. Stefanou A, et al. J Sleep Res. 2026 Jun;35(3):e70231. doi: 10.1111/jsr.70231. Epub 2025 Nov 2. J Sleep Res. 2026. PMID: 41177901 Free PMC article. Review.
Agomelatine, a melatoninergic antidepressant, is often prescribed to improve sleep disturbance, though meta-analytic evidence is currently lacking. ...Agomelatine was found to cause marginally more adverse effects than placebo (RR = 1.05, 95% CI: 1.00; 1.11). ...
Agomelatine, a melatoninergic antidepressant, is often prescribed to improve sleep disturbance, though meta-analytic evidence is curr …
Antidepressant efficacy of Agomelatine: Meta-analysis of placebo controlled and active comparator studies.
Maddukuri RK, Hema C, Sri Tejaswi K, Venkata Mounika M, Vegesana BP. Maddukuri RK, et al. Asian J Psychiatr. 2021 Nov;65:102866. doi: 10.1016/j.ajp.2021.102866. Epub 2021 Sep 20. Asian J Psychiatr. 2021. PMID: 34592623 Review.
Agomelatine is a novel antidepressant that was developed to counter the adverse effects associated with the standard SSRIs and SNRIs that limited their usage. ...In comparison (RR 0.99, 0.92-1.07) Agomelatine is an effective antidepressant having similar efficacy wi …
Agomelatine is a novel antidepressant that was developed to counter the adverse effects associated with the standard SSRIs and SNRIs …
Agomelatine as adjunctive therapy with SSRIs or SNRIs for major depressive disorder: a multicentre, double-blind, randomized, placebo-controlled trial.
Ju Y, Ou W, Chen H, Yang L, Long Y, Liang H, Xi Z, Huang M, Chen W, Lv G, Shao F, Liu B, Liu J, Li Z, Liao M, Liang W, Yao Z, Zhang Y, Li L. Ju Y, et al. BMC Med. 2025 Mar 5;23(1):137. doi: 10.1186/s12916-025-03951-0. BMC Med. 2025. PMID: 40038707 Free PMC article. Clinical Trial.
BACKGROUND: In general, traditional antidepressants often have limited efficacy in patients with major depressive disorder (MDD). Agomelatine, as an antidepressant with a different mechanism of action, might have adjunctive effects on traditional antidepressants. This stud …
BACKGROUND: In general, traditional antidepressants often have limited efficacy in patients with major depressive disorder (MDD). Agomela …
Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials.
Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C. Koesters M, et al. Br J Psychiatry. 2013 Sep;203(3):179-87. doi: 10.1192/bjp.bp.112.120196. Br J Psychiatry. 2013. PMID: 23999482
BACKGROUND: Agomelatine is a novel antidepressant drug with narrative, non-systematic reviews making claims of efficacy. ...Data extracted from three relapse prevention studies failed to show significant effects of agomelatine over placebo (relative risk 0.78, 99% C …
BACKGROUND: Agomelatine is a novel antidepressant drug with narrative, non-systematic reviews making claims of efficacy. ...Data extr …
Agomelatine versus other antidepressive agents for major depression.
Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Guaiana G, et al. Cochrane Database Syst Rev. 2013 Dec 17;2013(12):CD008851. doi: 10.1002/14651858.CD008851.pub2. Cochrane Database Syst Rev. 2013. PMID: 24343836 Free PMC article.
OBJECTIVES: The objective of this review was 1) to determine the efficacy of agomelatine in alleviating acute symptoms of major depressive disorder in comparison with other antidepressants, 2) to review the acceptability of agomelatine in comparison with other antid …
OBJECTIVES: The objective of this review was 1) to determine the efficacy of agomelatine in alleviating acute symptoms of major depre …
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N. Kishi T, et al. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17. Mol Psychiatry. 2023. PMID: 36253442 Free PMC article.
The meta-analysis comprised 34 studies (n = 9384, mean age = 43.80 years, and %females = 68.10%) on 20 antidepressants (agomelatine, amitriptyline, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirta …
The meta-analysis comprised 34 studies (n = 9384, mean age = 43.80 years, and %females = 68.10%) on 20 antidepressants (agomelatine, …
122 results